Literature DB >> 17483067

Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia.

Satoko Oka1, Taiji Yokote, Toshikazu Akioka, Satoshi Hara, Kichinosuke Kobayashi, Yuji Hirata, Nobuya Hiraoka, Motomu Tsuji, Toshiaki Hanafusa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17483067     DOI： 10.1532/IJH97.06223

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

Authors:  Emily Carpenter; Veronica Valverde-Garduno; Alex Sternberg; Chris Mitchell; Irene Roberts; Paresh Vyas; Ajay Vora
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

Review 2.  Lineage promiscuity in hemopoietic differentiation and leukemia.

Authors:  M F Greaves; L C Chan; A J Furley; S M Watt; H V Molgaard
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

3.  Trisomy 21 as the sole acquired karyotypic abnormality in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  T S Wan; W Y Au; J C Chan; L C Chan; S K Ma
Journal:  Leuk Res       Date:  1999-11       Impact factor: 3.156

4.  Unrelated donor bone marrow transplantation for acute mixed lineage (myeloid and B-lymphoid lineage) leukemia in an adult with Down syndrome.

Authors:  K Takagi; A Yoshida; K Kinoshita; D Iwashima; S Imamaura; H Iwasaki; H Tsutani; T Ueda
Journal:  Ann Hematol       Date:  2003-03-14       Impact factor: 3.673

5.  Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy.

Authors:  H M Kantarjian; C Hirsch-Ginsberg; G Yee; Y Huh; E J Freireich; S Stass
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

6.  Trisomy 21 in neoplastic cells.

Authors:  F Mitelman; S Heim; N Mandahl
Journal:  Am J Med Genet Suppl       Date:  1990

7.  Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia.

Authors:  S C Raimondi; C H Pui; D Head; F Behm; E Privitera; P K Roberson; G K Rivera; D L Williams
Journal:  Leukemia       Date:  1992-03       Impact factor: 11.528

8.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

Authors:  I F Khouri; J Romaguera; H Kantarjian; J L Palmer; W C Pugh; M Korbling; F Hagemeister; B Samuels; A Rodriguez; S Giralt; A Younes; D Przepiorka; D Claxton; F Cabanillas; R Champlin
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

9.  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL).

Authors:  M C Bene; M Bernier; R O Casasnovas; G Castoldi; W Knapp; F Lanza; W D Ludwig; E Matutes; A Orfao; C Sperling; M B van't Veer
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

10.  Lineage infidelity in acute leukemia.

Authors:  L J Smith; J E Curtis; H A Messner; J S Senn; H Furthmayr; E A McCulloch
Journal:  Blood       Date:  1983-06       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.